Compare Wahed FTSE USA Shariah ETF (HLAL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Mesoblast Limited — how do they compare? Wahed FTSE USA Shariah ETF trades at $75.91 (market cap $1.00B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 66 Days and Mesoblast Limited for 15 Days on average.
| HLAL | MESO | |
|---|---|---|
Market Cap | $1.00B | $1.75B |
Volume | 51,137 | 239,027 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $20.96 |
52-Week Low | $57.46 | $13.19 |
Typical Hold Time | 66 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $75.91, down 0.69% today, with a bullish technical signal from moving averages but bearish oscillators. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. A dividend of $0.10 is scheduled for September 2026, indicating a long-term income component. The stock shows mixed signals with strong moving average support but overbought RSI levels.
The outlook is cautiously optimistic due to bullish moving averages, but high RSI suggests near-term pullback risk. Investment opportunity lies in technical strength, while risks include lack of recent fundamental data and potential volatility from overbought conditions. Investors should await updated financials for a clearer picture.
Mesoblast (MESO) trades at $13.75, down 1.36% with bearish technical signals despite recent FDA approval for its Ryoncil potency assay. The company shows significant revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent milestones include completing Phase 3 trials for chronic back pain treatment, positioning the biotech firm for potential market expansion in the $10 billion back pain market.
Investment outlook balances promising commercial progress against persistent financial losses. The stock offers speculative growth potential through FDA-approved therapies and pipeline developments, but carries substantial risk from ongoing cash burn and competitive pressures in the regenerative medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
